Nuvation Bio Inc. (NUVB) financial statements and ratios from SEC XBRL: revenue $0.3B (TTM), net margin -325.3%, revenue growth 699.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $62.90M |
| Revenue (TTM) | $0.3B |
| Net Margin | -325.3% |
| Operating Margin (TTM) | -29.9% |
| Net Debt / EBITDA | 0.1 |
| Revenue Growth (YoY) | 699.0% |
| EPS Growth (YoY) | -71.6% |
| Price / Book | 9.58 |
| Price / Sales | 11.51 |
| Altman Z-Score | 2.14 (grey) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
NUVB overview · NUVB earnings · NUVB KPIs · NUVB documents · NUVB ownership · NUVB peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.